Developing next-generation targeted cancer immunotherapy treatments
iOmx Therapeutics is a clinical-stage company that harnesses deep tumor and myeloid biology insights to generate novel treatments for the most prevalent solid tumor indications. The company is translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs. Focused on developing drugs with single agent activity, iOmx is creating potential new backbone therapies in a modality-open fashion. By applying its comprehensive drug discovery & development expertise iOmx is committed to shaping the future of cancer therapy. iOmx is backed by international venture capital investors, such as Athos, Sofinnova Partners, Wellington Partners, MIG Capital, M Ventures and Arvantis Social Foundation Impact Investment. The Company is based in Martinsried/Munich, Germany.